ARCHIVES

New Immunotherapy Increased Survival Of Neuroblastoma In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 33 No. 9 | September 24, 2010

Download PDF Visit The Full Archive

Related Articles

Blinatumomab Demonstrates High Response Rate in ALL

June 29, 2012

Shubik Warns NCA Members They May Be Prober’s Next Target

May 22, 1981

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

February 17, 2012

NCI Plans Briefing Oct. 8 In St. Louis for SPORE Applicants

August 23, 1991

FDA Approves Rituxan For NHL With CHOP Therapy

February 24, 2006

Study Finds Long-Term Remission In NHL With Tositumomab, Iodine I 131 With CHOP

December 30, 2005